NYSE:HUM - Humana Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $240.69 +7.80 (+3.35 %) (As of 04/19/2019 02:30 PM ET)Previous Close$232.89Today's Range$233.7350 - $242.6252-Week Range$225.65 - $355.88Volume2.02 million shsAverage Volume1.27 million shsMarket Capitalization$32.65 billionP/E Ratio16.54Dividend Yield0.94%Beta0.93 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health and voluntary insurance benefits; financial protection products; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE South Region contract. Further, it offers pharmacy solutions, provider services, predictive modeling and informatics services, and clinical care services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2018, the company had approximately 17 million members in medical benefit plans, as well as approximately 6 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky. Receive HUM News and Ratings via Email Sign-up to receive the latest news and ratings for HUM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Hospital & medical service plans Sub-IndustryManaged Health Care SectorMedical Current SymbolNYSE:HUM Previous Symbol CUSIP44485910 CIK49071 Webwww.humana.com Phone502-580-1000Debt Debt-to-Equity Ratio0.43 Current Ratio1.68 Quick Ratio1.68Price-To-Earnings Trailing P/E Ratio16.54 Forward P/E Ratio13.75 P/E Growth1.05 Sales & Book Value Annual Sales$56.91 billion Price / Sales0.57 Cash Flow$17.8025 per share Price / Cash Flow13.52 Book Value$74.95 per share Price / Book3.21Profitability EPS (Most Recent Fiscal Year)$14.55 Net Income$1.68 billion Net Margins2.96% Return on Equity19.64% Return on Assets6.68%Miscellaneous Employees41,600 Outstanding Shares135,638,000Market Cap$32.65 billion Next Earnings Date5/1/2019 (Confirmed) OptionableOptionable Humana (NYSE:HUM) Frequently Asked Questions What is Humana's stock symbol? Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM." How often does Humana pay dividends? What is the dividend yield for Humana? Humana announced a quarterly dividend on Friday, February 8th. Investors of record on Friday, March 29th will be given a dividend of $0.55 per share on Friday, April 26th. This represents a $2.20 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, March 28th. This is a boost from Humana's previous quarterly dividend of $0.50. View Humana's Dividend History. How will Humana's stock buyback program work? Humana announced that its Board of Directors has initiated a stock buyback program on Friday, December 15th 2017, which allows the company to repurchase $3,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its stock is undervalued. How were Humana's earnings last quarter? Humana Inc (NYSE:HUM) announced its quarterly earnings results on Wednesday, February, 6th. The insurance provider reported $2.65 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.12. The insurance provider earned $14.17 billion during the quarter, compared to analysts' expectations of $14.04 billion. Humana had a net margin of 2.96% and a return on equity of 19.64%. The business's quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.06 earnings per share. View Humana's Earnings History. When is Humana's next earnings date? Humana is scheduled to release their next quarterly earnings announcement on Wednesday, May 1st 2019. View Earnings Estimates for Humana. How can I listen to Humana's earnings call? Humana will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8886257430. What guidance has Humana issued on next quarter's earnings? Humana issued an update on its FY19 earnings guidance on Wednesday, February, 6th. The company provided EPS guidance of $17.00-17.50 for the period, compared to the Thomson Reuters consensus estimate of $17.48. Humana also updated its FY 2019 guidance to $17.00-17.50 EPS. What price target have analysts set for HUM? 16 Wall Street analysts have issued 12-month price targets for Humana's shares. Their predictions range from $275.02 to $418.00. On average, they expect Humana's stock price to reach $355.5013 in the next twelve months. This suggests a possible upside of 47.7% from the stock's current price. View Analyst Price Targets for Humana. What is the consensus analysts' recommendation for Humana? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Humana. What are Wall Street analysts saying about Humana stock? Here are some recent quotes from research analysts about Humana stock: 1. According to Zacks Investment Research, "Humana’s shares have lost year-to-date against its industry’s gain. Moreover, the company has witnessed its 2020 earnings estimates move south over the last 30 days. Its rising level of expenses since 2010 persistently weighs on the bottom line. The company expects high benefit expenses which will lead to an overall increase in operating expenses going forward. Also, increase in leverage might lead to heightened financial risk for the company and burden on margins. Nevertheless, it is well-poised for growth on the back of its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters." (4/11/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on HUM shares and maintain our 12-month price target of $325. After the market close on the company reaffirmed its 2018 EPS guidance. The company also provided updated 2019 membership metrics. Given the update, we are increasing our 2019 revenue and EPS estimates. The company had previously indicated that it expected 2019 adjusted EPS to grow above its stated long-term goal of 11-15%. With its filing on Wednesday, the company did not comment on 2019 EPS guidance, but will provide detailed 2019 financial guidance when it reports 4Q18 and year-end 2018 results on Wednesday, February 6, 2019." (1/2/2019) Has Humana been receiving favorable news coverage? Media coverage about HUM stock has been trending very positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Humana earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned news headlines about the insurance provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of Humana's key competitors? Some companies that are related to Humana include Aetna (AET), Anthem (ANTM), Cigna (CI), Centene (CNC), WellCare Health Plans (WCG), Molina Healthcare (MOH), Trupanion (TRUP) and Advanzeon Solutions (CHCR). What other stocks do shareholders of Humana own? Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), Boeing (BA), Alibaba Group (BABA), Mastercard (MA), Netflix (NFLX), NVIDIA (NVDA), General Electric (GE), Visa (V), Gilead Sciences (GILD) and Walt Disney (DIS). Who are Humana's key executives? Humana's management team includes the folowing people: Mr. Bruce Dale Broussard, Pres, CEO & Director (Age 57)Mr. Brian Andrew Kane, Chief Financial Officer (Age 46)Mr. Timothy S. Huval, Chief HR Officer (Age 53)Ms. Jody L. Bilney, Chief Consumer Officer (Age 58)Dr. William Kevin Fleming Pharm.D., PharmD, RPh, Segment Pres of Healthcare Services (Age 51) Who are Humana's major shareholders? Humana's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Calamos Advisors LLC (0.23%), Strs Ohio (0.11%), Rhenman & Partners Asset Management AB (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%) and DNB Asset Management AS (0.04%). Company insiders that own Humana stock include Brian P Leclaire, Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, M Todoroff Christopher, Roy A Beveridge, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming. View Institutional Ownership Trends for Humana. Which institutional investors are selling Humana stock? HUM stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Scout Investments Inc., Meeder Asset Management Inc., State of Alaska Department of Revenue, Rhenman & Partners Asset Management AB, Eqis Capital Management Inc., First Hawaiian Bank and Pensionfund Sabic. Company insiders that have sold Humana company stock in the last year include Bruce D Broussard, Christopher H Hunter, Cynthia H Zipperle, David A Jr/Ky Jones, Elizabeth D Bierbower, Heidi S Margulis, Jody L Bilney, Roy A Beveridge, Timothy Alan Wheatley and William Kevin Fleming. View Insider Buying and Selling for Humana. Which institutional investors are buying Humana stock? HUM stock was bought by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, Strs Ohio, PGGM Investments, Pacer Advisors Inc., Sciencast Management LP, Highland Capital Management LLC, Tealwood Asset Management Inc. and Tributary Capital Management LLC. View Insider Buying and Selling for Humana. How do I buy shares of Humana? Shares of HUM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Humana's stock price today? One share of HUM stock can currently be purchased for approximately $240.69. How big of a company is Humana? Humana has a market capitalization of $32.65 billion and generates $56.91 billion in revenue each year. The insurance provider earns $1.68 billion in net income (profit) each year or $14.55 on an earnings per share basis. Humana employs 41,600 workers across the globe. What is Humana's official website? The official website for Humana is http://www.humana.com. How can I contact Humana? Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The insurance provider can be reached via phone at 502-580-1000 or via email at [email protected] MarketBeat Community Rating for Humana (NYSE HUM)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 710 (Vote Outperform)Underperform Votes: 766 (Vote Underperform)Total Votes: 1,476MarketBeat's community ratings are surveys of what our community members think about Humana and other stocks. Vote "Outperform" if you believe HUM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HUM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/19/2019 by MarketBeat.com StaffFeatured Article: What is a Buy-Side Analyst?